drug · small molecule
ALYFTREK
updated 6mo agoby $VERX Vertex, Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval, with an approval for cystic fibrosis.
targets
Cystic fibrosis transmembrane conductance regulator
all catalysts(0)
nothing on the calendar yet
Trials studying ALYFTREK
News(6)
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.biopharma_dive · 13d ago
- ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s handsAfter achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia th…biospace · 1mo ago
- Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vagueAntibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.fiercebiotech · 3mo ago
- Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchiseA surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.biospace · 3mo ago
- Vertex’s biggest overhang: a rival 50 times smallerDespite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.biopharma_dive · 3mo ago
- Vertex earnings get muted investor responseWhile overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.biopharma_dive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that